Increasing Rates of Contralateral Prophylactic Mastectomy Among Patients With Ductal Carcinoma In Situ

被引:283
作者
Tuttle, Todd M. [1 ]
Jarosek, Stephanie
Habermann, Elizabeth B.
Arrington, Amanda
Abraham, Anasooya
Morris, Todd J.
Virnig, Beth A.
机构
[1] Univ Minnesota, Sch Med, Dept Surg, Div Surg Oncol, Minneapolis, MN 55455 USA
关键词
RANDOMIZED CONTROLLED-TRIAL; SURGICAL ADJUVANT BREAST; CANCER; WOMEN; PROJECT; TAMOXIFEN; EFFICACY; RISK;
D O I
10.1200/JCO.2008.20.1681
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Some women with unilateral ductal carcinoma in situ (DCIS) undergo contralateral prophylactic mastectomy (CPM) to prevent cancer in the opposite breast. The use and trends of CPM for DCIS in the United States have not previously been reported. Methods We used the Surveillance, Epidemiology, and End Results database to analyze the initial treatment (within 6 months) of patients with unilateral DCIS diagnosed from 1998 through 2005. We determined the CPM rate as a proportion of all surgically treated patients and as a proportion of all patients who underwent mastectomy. We compared demographic and tumor variables in women with unilateral DCIS who underwent surgical treatment. Results We identified 51,030 patients with DCIS; 2,072 patients chose CPM. The CPM rate was 4.1% for all surgically treated patients and 13.5% for patients undergoing mastectomy. Among all surgically treated patients (including breast-conserving surgery), the CPM rate increased by 148% from 1998 (2.1%) to 2005 (5.2%). Among patients who underwent mastectomy to treat DCIS (excluding patients undergoing breast-conserving surgery), the CPM rate increased by 188% from 1998 (6.4%) to 2005 (18.4%). Young patient age, white race, recent year of diagnosis, and the presence of lobular carcinoma in situ were significantly associated with higher CPM rates among all surgically treated patients and all patients undergoing mastectomy. Large tumor size and higher grade were significantly associated with increased CPM rates among all surgically treated patients but lower CPM rates among patients undergoing mastectomy. Conclusion The use of CPM for DCIS in the United States markedly increased from 1998 through 2005.
引用
收藏
页码:1362 / 1367
页数:6
相关论文
共 16 条
[1]   Trends in the treatment of ductal carcinoma in situ of the breast [J].
Baxter, NN ;
Virnig, BA ;
Durham, SB ;
Tuttle, TM .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (06) :443-448
[2]   Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial [J].
Fisher, B ;
Dignam, J ;
Wolmark, N ;
Wickerham, DL ;
Fisher, ER ;
Mamounas, E ;
Smith, R ;
Begovic, M ;
Dimitrov, NV ;
Margolese, RG ;
Kardinal, CG ;
Kavanah, MT ;
Fehrenbacher, L ;
Oishi, RH .
LANCET, 1999, 353 (9169) :1993-2000
[3]   Pathologic variables predictive of breast events in patients with ductal carcinoma in situ [J].
Fisher, Edwin R. ;
Land, Stephanie R. ;
Saad, Reda S. ;
Fisher, Bernard ;
Wickerham, D. Lawrence ;
Wang, Meihua ;
Costantino, Joseph P. ;
Wolmark, Norman .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2007, 128 (01) :86-91
[4]  
Fisher ER, 1999, CANCER-AM CANCER SOC, V86, P429, DOI 10.1002/(SICI)1097-0142(19990801)86:3<429::AID-CNCR11>3.0.CO
[5]  
2-Y
[6]   Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: A population-based study [J].
Gao, X ;
Fisher, SG ;
Emami, B .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (04) :1038-1045
[7]   Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial [J].
George, WD ;
Houghton, J ;
Austoker, J ;
Bishop, H ;
Cuzick, J ;
Fentiman, IS ;
Forbes, JF ;
Foster, E ;
Ellis, I ;
Leinster, S ;
Spittle, M ;
Joslin, C ;
Stewart, H ;
Baum, M ;
Campbell, R ;
Elston, C ;
Stroner, P ;
Taylor, I ;
Teasdale, C ;
Cooke, T ;
MacPherson, K ;
Priestman, T ;
Sloane, J ;
Houghton, J ;
Williams, N ;
Riley, D ;
Moritz, S ;
Wells, U ;
Bellenger, K ;
Coles, E ;
Chan, J ;
Foster, E ;
Stroner, P ;
MacDonald, C ;
Douglas, A ;
Campbell, R ;
Forbes, JF ;
Wilson, A ;
Hornery, S ;
Lindsay, D .
LANCET, 2003, 362 (9378) :95-102
[8]   Contralateral prophylactic mastectomy - Predictors of significant histologic findings [J].
Goldflam, K ;
Hunt, KK ;
Gershenwald, JE ;
Singletary, SE ;
Mirza, N ;
Kuerer, HM ;
Babiera, GV ;
Ames, FC ;
Ross, MI ;
Feig, BW ;
Sahin, AA ;
Arun, B ;
Meric-Bernstam, F .
CANCER, 2004, 101 (09) :1977-1986
[9]   Efficacy of prophylactic mastectomy in women with unilateral breast cancer: A cancer research network project [J].
Herrinton, LJ ;
Barlow, WE ;
Yu, OC ;
Geiger, AM ;
Elmore, JG ;
Barton, MB ;
Harris, EL ;
Rolnick, S ;
Pardee, R ;
Husson, G ;
Macedo, A ;
Fletcher, SW .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (19) :4275-4286
[10]  
KATIPAMULA R, 2008, J CLIN ONCOL S, V26, pS9